Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
What if the real mass adoption of these drugs was in front of us
Chung, C.-C
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
For weight management, Wegovy is also approved for use in adolescents aged 12 years and older with obesity
Elke batch bevat een Analysecertificaat
